Long-term effects of cholinesterase inhibitors and memantine on cognitive decline, cardiovascular events, and mortality in dementia with Lewy bodies: An up to 10-year follow-up study.

Xu, Hong; Habich, Annegret; Ferreira, Daniel; Elisabet, Londos; Westman, Eric; Eriksdotter, Maria (2024). Long-term effects of cholinesterase inhibitors and memantine on cognitive decline, cardiovascular events, and mortality in dementia with Lewy bodies: An up to 10-year follow-up study. (In Press). Alzheimer's & dementia Elsevier 10.1002/alz.14118

[img]
Preview
Text
Alzheimer_s___Dementia_-_2024_-_Xu_-_Long_term_effects_of_cholinesterase_inhibitors_and_memantine_on_cognitive_decline_.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (2MB) | Preview

INTRODUCTION

We aimed to assess the impact of cholinesterase inhibitors (ChEIs) and memantine on cognition, major adverse cardiovascular events (MACE) and mortality in dementia with Lewy bodies (DLB).

METHODS

A total of 1,095 incident DLB patients from the Swedish Registry on cognitive/dementia disorders were included. Using an inverse probability of treatment weighting, the effect of initiating ChEI or memantine within 90 days of DLB diagnosis and nonuse was evaluated on cognitive trajectories and risks of MACE and death.

RESULTS

The use of ChEIs significantly slowed cognitive decline at follow-ups (Mini-Mental State Examination [MMSE] -0.39 points/y; 95% confidence interval [CI], -0.96 to 0.18) compared to memantine (-2.49 points/y; -4.02 to -0.97) and nonuse (-2.50 points/y; -4.28 to -0.73). Treatment groups did not differ in MACE events. ChEI use was associated with lower risk of death in the first year after DLB diagnosis (adjusted hazard ratio [HR] 0.66, 95% CI 0.46, 0.94).

DISCUSSION

Our findings illuminate the potential benefits of ChEI treatment in DLB patients.

HIGHLIGHTS

Cholinesterase inhibitors slow cognitive decline over a 5-year follow-up period when compared to both memantine treatment and nonuse in patients with dementia with Lewy bodies. Cholinesterase Inhibitors reduce risk of mortality within the initial year, but this effect is not sustained after 1 year in patients with dementia with Lewy bodies.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > University Psychiatric Services > University Hospital of Psychiatry and Psychotherapy

UniBE Contributor:

Habich, Annegret

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1552-5279

Publisher:

Elsevier

Language:

English

Submitter:

Pubmed Import

Date Deposited:

26 Aug 2024 08:49

Last Modified:

27 Aug 2024 21:26

Publisher DOI:

10.1002/alz.14118

PubMed ID:

39177108

Uncontrolled Keywords:

MMSE cholinesterase inhibitors dementia with Lewy bodies memantine mortality

BORIS DOI:

10.48350/199962

URI:

https://boris.unibe.ch/id/eprint/199962

Actions (login required)

Edit item Edit item
Provide Feedback